MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$79.95M

FY 2025 · Annual

Investing Cash Flow

-$83.70M

FY 2025 · Annual

Financing Cash Flow

$189.59M

FY 2025 · Annual

-19.0% YoY

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$87.0M
+ D&A$248.0K
+ Stock-Based Comp$8.7M
+ Deferred Tax$0
+ Working Capital$1.6M
- Other Non-Cash-$3.5M
= Operating Cash Flow-$79.9M
- Capex-$1.9M
= Free Cash Flow-$81.9M

Analysis

FY2025 free cash flow is -$81.9M. FCF conversion is 94.1% of net income. Operating cash flow was -$79.9M, with capex of -$1.9M. The largest bridge item is Stock-Based Comp at $8.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
S-8S-8 filingNov 10, 2026
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 5, 2026

Does MBX generate free cash flow?

MBX Biosciences, Inc. Common Stock (MBX) generated -$81.88M of free cash flow in fiscal 2025.

How much operating cash flow does MBX produce?

Operating cash flow was -$79.95M, before capital expenditures of $1.93M.